Positron emission tomography/computed tomography [PET/CT] is a well-established nuclear medicine
hybrid
imaging modality with high sensitivity and accuracy afforded by the combination of functional and
anatomical information. Up until now, fluorine 18 fluorodeoxyglucose [18F-FDG] has been the
workhorse radiopharmaceutical of oncological and neurological PET/CT imaging. However, its main
limitation is its nonspecific nature, as the tracer can be taken up by both malignant tumors and inflamed tissues. Newer radiopharmaceuticals are able to retain high sensitivity for cancers with improvements in specificity; this can further improve the accuracy and robustness of PET/CT. In this case series, the authors report on their experiences with 4 cases of 18F-FLT, 3 cases of
11C-PiB, 3 cases of 18F-THK5351, and 3 cases of 68Ga- PSMA PET/CT, highlighting the benefits of these novel non-FDG PET radiopharmaceuticals.

Keywords: PET/CT, Non-FDGPET radiopharmaceuticals, 18F-FLT, 11C-PiB, 18F-THK5351, 68Ga-PSMA